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Introduction
The thrombotic tendency in antiphospholipid
syn drome (APS) shares several pathways with athe ro -
sclerosis (1). The antiphospholipid syndrome is an
acquired thrombotic disorder characterized by venous
and arterial thromboses and/or spontaneous abor -
tions and repeated detection of antiphospholipid
antibodies. The APS may be associated with another
autoimmune disease (secondary APS = SAPS), or
unrelated to an underlying disease (primary APS =
PAPS) (2). 
Antiphospholipid antibodies are the main se ro -
logical finding in patients with antiphospholipid syn dro -
me (APS), but patients with athero scle ro sis also have
elevated levels of the above-mentioned antibodies (3). 
Atherothrombosis (atherosclerosis superi m -
po sed by thrombosis) is influenced by nonmodifiable
risk factors (age, gender, race/ethnicity, family histo ry),
well-documented modifiable risk factors (hyper -
tension, diabetes, hiperlipidemia, smoking). Less
well-documented or potentially modifiable risk factors
are obesity (Body Mass Index, BMI ≥ 30), physical
inactivity, alcohol abuse, hyperhomocysteinemia.
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Kratak sadr`aj: Tromboti~na tendencija u antifos foli -
pidnom sindromu (APS) deli nekoliko zajedni~kih putanja
sa aterosklerozom. Na aterotrombozu (ateroskleroza sa su -
perimponiranim trombozama) uti~u nepromenljivi i
promenljivi faktori rizika (pu{enje, gojaznost, fizi~ka
neaktivnost, zloupotreba alkohola, hiperhomocisteinemija).
Stoga smo ispitali vezu izme|u klini~kih i serolo{kih
osobina pacijenata sa primarnim APS-om i potencijalno
promenljivih faktora rizika za razvoj aterotromboze. Tako|e,
uporedili smo analizirane parametre sa kontrolom.
Koncen tracije homocisteina utvr|ene su metodom HPLC
(te~na hromatografija visoke rezolucije) a antifosfolipidna
antitela metodom ELISA. Pu{a~i su imali povi{ene nivoe
homocisteina (c2 = 6,22, p<0,05). Nezavisno od godina
pacijenata, otkrivena je veza izme|u povi{enih nivoa homo -
cisteina i istorije infarkta miokarda (c2 = 4,61, p<0,05).
Hiperhomocisteinemija i pu{enje su najva`niji promenljivi
faktori rizika za aterotrombozu u primarnom antifosfo lipid -
nom sindromu. 
Klju~ne re~i: hiperhomocisteinemija, pu{enje, primarni
antifosfolipidni sindrom, infarkt miokarda
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Summary: The thrombotic tendency in anti phos pholipid
syndrome (APS) shares several pathways with atheroscle -
rosis. Atherothrombosis (atherosclerosis superi m posed with
thromboses) is influenced by nonmodifiable and some
modifiable risk factors (smoking, obesity, physical inactivity,
alcohol abuse, hyperhomocysteinemia). Therefore, we
investigated the association among clinical and serological
features of patients with primary APS and potentially mo -
difiable risk factors for the development of atherothrom -
bosis. Also, we compared the analyzed parameters with
those in control subjects. Ho mo cysteine concentrations
were detected by HPLC (high performance liquid chroma -
tography), while antipho spho lipid antibodies were detected
by ELISA. Smokers had elevated levels of homocysteine (c2
= 6.22, p < 0.05). Indepen dently of patients’ age, the
association bet ween increased levels of homocysteine and
history of myo cardial infarctions was found (c2 = 4.61, p <
0.05).  Hyperho mo cysteinemia and smoking are the most
important mo difiable risk factors for atherothrombosis in
primary APS.
Keywords: hyperhomocysteinemia, smoking, primary
antiphospholipid syndrome, myocardial infarction
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The aim of this study was to investigate the
association among the clinical and serological
features of patients with primary antiphospholipid
syndrome (PAPS) and potentially modifiable risk
factors for the development of atherothrombosis.
Also, we compa red the analyzed parameters with
those in healthy control subjects.
Patients and Methods
This study included 33 patients (24 women and
nine men) with primary antiphospholipid syndrome,
according to the updated and revised Sapporo criteria
(4, 5). The mean age of the analyzed patients was 41
± 14, the age ranging from 21 to 78 years. Also, this
study included 28 healthy control subjects (21
women and seven men). The mean age of the control
subjects was 37 ± 12, ranging from 18 to 72 years. 
The criterion for the selection of sera for this
study was similar age of all participants. Exclusion
criteria for control subjects were the presence of
acute or chro nic diseases and taking medications,
because we wanted to avoid any possible interference
with the analy zed parameters. Regarding the fact that
APS is a chro nic, autoimmune disease, investigated
patients were on antithrombotic drugs and/or oral
anticoagulants for which no interaction with the
analyzed parameters ha s been reported. Last dose of
the previously mentioned medications was taken 12h
before venipuncture.
Our study was approved by the local Ethical
Com mittee and all participants provided signed
informed consent.
The weight status of the patients is defined by
the body mass index (BMI) (weight (kilograms) divided
by the square of height in meters). Persons with a BMI
of 25 to 29.9 kg/m2 are classified as being overweight,
and tho se with a BMI of ≥ 30  are classified as being
obese (6). 
Features of the investigated subjects are shown
in Table I.
Methods 
After overnight fasting (12 hours) and after 24
hours without intensive physical activity, blood
samples were collected for serum and plasma from
an arm vein (antecubital vein), and then centrifuged
for 10 minutes at 3000 revolutions per minute. For
the purpose of avoiding falsely positive higher levels
of homocysteine, serum was separated from
coagulum in 45 minutes (7). 
Concentrations of homocysteine were detected
by HPLC (high performance liquid chromatography)
using commercial reagents from BIORAD, München,
Germany and the fluorescent detector Hewlett-
Packard 1046A.
Anticardiolipin antibodies of the IgG and of the
IgM isotype were determined using commercial kits
of Varelisa Pharmacia Deutschland GmbH, Diagno -
stics Division, Freiburg, Germany. Commercial kits
from IMTEC Immunodiagnostica, GmbH, Berlin,
Germany, were used for the determination of anti-
b2glycoprotein I antibodies of the IgG and the IgM
isotype (8, 9). 
The presence of lupus anticoagulant was esti -
 mated according to the recommendations of the Inter -
na tional Society of Thrombosis and Haemostasis (10). 
Statistical analysis
Continous variables were expressed as mean ±
SD. Descriptive statistics were used to summarize the
clinical characteristics of patients with PAPS. The
association between the clinical features of APS and
analyzed parameters was examined by c2-test, Mann-
Whitney or t-test, when appropriate. The correlation
between two quantitative variables was determined
with the Spearman’s correlation test. Logistic regre s -
sion was performed with the APS-related clinical
events as the dependent variable and those investi -
gated parameters whose association with the clinical
event was statistically significant in the preceding
analysis as the independent variables. Comparison
among the groups of investigated subjects was done
by Mann-Whitney or t-test, when appropriate. In all of
the above-mentioned tests, p < 0.05 was considered
statistically significant (11). Analyses were conducted
in SPSS 10 (SPSS, Inc, Chicago, IL, USA).
Patients
(n = 33)
Control
subjects
(n = 28)
Smoking           Smokers
Nonsmokers
10/33 9/28
23/33 19/28
BMI* < 25
25–29.9
≥ 30
14/33 27/28
16/33 1/28
3/33 0/28
Physical activity  Training
Recreative
Passive
0/33 6/28
3/33 3/28
30/33 19/28
Alcohol             Abstention
Ocassionally
32/33 23/28
1/33 5/28
* BMI (Body Mass Index), calculated on the basis of data for weight
and height of the analyzed subjects, according to formula
m(kg)/h2(m)
Table I Features of investigated subjects.
Results
Arterial events were present in 60.61% (20/33)
of the investigated patients while non-arterial events
were present in 39.39% (13/33) of patients. Myocar -
dial infarctions were present in 30% (6/20), while
cere bro vascular insults and peripheral arterial
thromboses were present in 70% (14/20) of patients
with arterial events. Deep venous thromboses compli -
cated by pulmonary emboli were present in 53.85%
(7/13) and recurrent abortions were present in
46.15% (6/13) of patients with non-arterial events. 
In the analyzed patients, independently of their
age, we found an association between increased
levels of homocysteine and history of myocardial
infarction (c2 = 4.61, p < 0.05), but logistic regres -
sion failed to confirm the strength of the association. 
Homocysteine concentrations did not correlate
with the concentrations of antiphospholipid antibo dies. 
Patients with PAPS in comparison to control
subjects had significantly elevated concentrations
(U/mL) of: anticardiolipin antibodies of the IgG
isotype [(193.10 ± 173.47) vs. (14.98 ± 9.12), p <
0.001], anticardiolipin antibodies of the IgM isotype
((184.76 ± 190.92) vs. (11.22 ± 6.69), p< 0.001),
anti-b2gpI antibodies of the IgG isotype ((32.57 ±
37.70) vs. (3.13 ± 1.82), p < 0.001), anti-b2gpI
antibodies of the IgM isotype ((20.63 ± 35.41) vs.
(1.97 ± 1.19), p < 0.001).
No statistically significant difference was found
between the mean concentrations (mmol/L) of
homocy steine in PAPS patients and in healthy control
subjects [(10.86 ± 3.69) vs. (9.39 ± 2.01), t-test, p
= not significant].
Only 9.09% (3/33) of the investigated patients
and none of the control subjects were obese, which is
shown in Table I.
Alcohol abusers were not among the analyzed
subjects. Only 3.03% (1/33) of the analyzed patients
and 17.85% (5/28) of the control subjects were
occasionally consuming alcohol.
Among the analyzed subjects, 30.30% (10/33)
of patients and 32.14% (9/28) of control subjects
were smokers. Compared to nonsmokers, smokers
had elevated levels of homocysteine (c2 = 6.22, p <
0.05), although the logistic regression could not
confirm the strength of this finding. 
Discussion
Previously it was reported that elevated plasma
homocysteine is an independent risk factor for peri p -
heral vascular, cerebrovascular and coronary heart
disease. The increased risk of CHD associated with
homocysteine is additive to that of conventional
vascular risk factors (12). According to Avivi (13),
elevated levels of homocysteine were associated with
thromboembolic complications and Stauffenberger et
al. (14) showed that levels of homocysteine are in
correlation with the rate of progression of coronary
arteries stenosis in women. In the analyzed patients,
independently of their age, we found an association
between the increased levels of homocysteine and
history of myocardial infarctions. We did not find any
difference in the mean concentrations of homocy -
steine between the PAPS patients and control
subjects. 
Smoking has both acute effects on the risk of
thrombus formation in narrowed arteries and chronic
effects related to an increased burden of atheroscle -
rosis (15), and the significant association between
homocysteine and thromboses was reported (16).
Thromboses are the main clinical finding in PAPS and
the patients who were smokers had increased
concen trations of homocysteine.
According to Sofi et al. (17) leisure time
physical activity is inversely related to BMI obesity is
associated with passive life and generally it is a
predisposition for cardiovascular diseases. Among the
analyzed patients with PAPS, only 9.09% had BMI ≥
30 and no association between obesity and the analy -
zed parameters was found. 
Our results suggest that among the inve sti gated
modifiable risk factors for the development of
atherothrombosis, hyperhomocysteinemia and smo -
king are the most important in patients with primary
antiphospholipid syndrome. Although the results could
be considered as preliminary because of the relatively
small number of subjects involved, we strongly re -
commend that smoking cessation, as well as deter mi -
na tion of homocysteine levels and their normali zation
to recommended values, should be advised to all
patients with the primary antiphospholipid syndrome. 
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